Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …

Fragility fractures are increasingly recognized as a complication of both type 1 and type 2
diabetes, with fracture risk that increases with disease duration and poor glycemic control …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …

Objective To estimate the association between the use of sodium glucose co-transporter-2
(SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies. Design …

Background Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with
improved cardiovascular and kidney outcomes. However, the magnitude and potential …

Introduction: Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are recommended
after metformin for a large spectrum of patients with type 2 diabetes, because of a favorable …

Diabetes is a highly prevalent disease with complications that impact most bodily systems.
However, the impact of diabetes on bone health is frequently ignored or underestimated …

Abstract Type 2 diabetes (T2 DM) is a rapidly growing public health problem. It is associated
with an increased risk of fracture, particularly of the hip, despite normal or high bone mineral …

There is substantial, and growing, evidence that type 2 diabetes (T2D) is associated with
skeletal fragility, despite often preserved bone mineral density. As post-fracture outcomes …